Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.
作者信息
Kamat Ashish M, Lerner Seth, Black Peter, Bellmunt Joaquim, Dinney Colin, Hahn Noah M, O'Donnell Michael, Quale Diane Z
机构信息
Department of Urology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Department of Urologic Oncology, Baylor College of Medicine, TCGA Bladder Cancer, Houston, TX, USA.
出版信息
Bladder Cancer. 2017 Jul 27;3(3):145-146. doi: 10.3233/BLC-170118.
Abstract
摘要
相似文献
1
Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.一旦对卡介苗无反应，永远对卡介苗无反应：致美国食品药品监督管理局的一封公开信，呼吁加强膀胱癌临床试验的受试者招募工作
Bladder Cancer. 2017 Jul 27;3(3):145-146. doi: 10.3233/BLC-170118.
2
Current advances in BCG-unresponsive non-muscle invasive bladder cancer.BCG 无应答性非肌肉浸润性膀胱癌的最新进展。
Expert Opin Investig Drugs. 2019 Sep;28(9):757-770. doi: 10.1080/13543784.2019.1655730. Epub 2019 Aug 15.
3
Current Clinical Trials in Non-muscle Invasive Bladder Cancer.非肌肉浸润性膀胱癌的当前临床试验
Curr Urol Rep. 2018 Oct 24;19(12):101. doi: 10.1007/s11934-018-0852-6.
4
Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.美国食品和药物管理局定义的卡介苗无反应性疾病的预后意义。
Eur Urol. 2019 Jan;75(1):8-10. doi: 10.1016/j.eururo.2018.09.028. Epub 2018 Oct 6.
5
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.CG0070溶瘤病毒方案治疗卡介苗无反应性非肌层浸润性膀胱癌患者安全性和有效性的开放标签、单臂、II期多中心研究：中期结果
Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26.
6
Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients.草分枝杆菌细胞壁核酸复合物（MCNA）对卡介苗无反应患者的疗效
Bladder Cancer. 2017 Jan 27;3(1):65-71. doi: 10.3233/BLC-160084.
7
Current clinical trials in non-muscle invasive bladder cancer.非肌肉浸润性膀胱癌的当前临床试验。
Urol Oncol. 2017 Aug;35(8):516-527. doi: 10.1016/j.urolonc.2017.06.043.
8
Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.免疫疗法在卡介苗无反应性非肌肉浸润性膀胱癌中的作用。
Urol Oncol. 2018 Mar;36(3):103-108. doi: 10.1016/j.urolonc.2017.12.020. Epub 2018 Feb 9.
9
Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.致编辑的信：卡介苗（BCG）治疗非肌层浸润性膀胱癌失败：BCG无反应性疾病的数据驱动定义
Bladder Cancer. 2017 Jul 27;3(3):147-148. doi: 10.3233/BLC-179020.
10
Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.卡介苗挽救治疗：定义与背景。
Urol Clin North Am. 2020 Feb;47(1):1-4. doi: 10.1016/j.ucl.2019.09.002.
引用本文的文献
1
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.经卡介苗膀胱内灌注后非肌层浸润性膀胱癌的膀胱保留治疗疗效的系统评价
Eur Urol. 2020 Sep;78(3):387-399. doi: 10.1016/j.eururo.2020.02.012. Epub 2020 Mar 4.
2
Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.非肌层浸润性膀胱癌膀胱内治疗的最新进展：如何、何时以及何种治疗。
World J Urol. 2019 Oct;37(10):2017-2029. doi: 10.1007/s00345-018-2591-1. Epub 2018 Dec 7.
3
Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer.癌症免疫疗法：PD-1在卡介苗复发膀胱癌中的预后意义及对治疗的启示
Ann Surg Oncol. 2018 Sep;25(9):2498-2499. doi: 10.1245/s10434-018-6610-7. Epub 2018 Jul 3.
本文引用的文献
1
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.非肌层浸润性膀胱癌的定义、终点指标及临床试验设计：国际膀胱癌小组的建议
J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25.
2
Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG.膀胱内卡介苗治疗患者后膀胱癌疾病状态的阐明
Bladder Cancer. 2015 Mar 30;1(1):29-30. doi: 10.3233/BLC-159002.
Zotero 插件